🔈 We are thrilled to share that the MAINTAIN POP trial was submitted, in collaboration with REMIND, to the ANSM Agence nationale de sécurité du médicament et des produits de santé.

MAINTAIN POP is a phase II randomized placebo-controlled trial which will assess the safety and efficacy of EXL01, a single-strain live biotherapeutic, against endoscopic endpoints in patients with Crohn’s disease that have been successfully brought into remission by surgery.

The trial will take place across 13 sites in the REMIND group, a network of specialist gastroenterologists in IBD across France.